Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05507177
Other study ID # 10506
Secondary ID 10140022010002
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 7, 2023
Est. completion date August 2025

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The researchers will investigate the effects of a communication training for community pharmacists and general physicians that aims to make it easier for them to stop or lower medication for cardiovascular disease and/or diabetes in older patients. The researchers expect that trained community pharmacists and general physicians will stop or lower medication for cardiovascular disease and/or diabetes in more patients compared to untrained community pharmacists and general physicians. The researchers will recruit local teams consisting of a community pharmacist and one or more general physician, and allocate each team to either group I or group II. All teams in group I are first being trained, before they conduct a study-specific clinical medication review in 10 patients per team. All teams in group II will first conduct a more general clinical medication review in 10 patients per team too, before receiving the training. Patients will only be included after meeting in- and exlcusion criteria and signing an informed consent form. During the conduct of the study, the researchers will collect patient reported data and data on the conduct of the medication reviews. Retrospectively, the researchers will also collect data on the medication use of the patients from the pharmacy information system and specific medical data related to cardiometabolic disease of the patients from the physician's information system. The researchers will also assess the total costs and benefits of the intervention, and evaluate the training for the purpose of future implementation.


Description:

RESEARCH QUESTION: The researchers will investigate the effects of a communication training program for community pharmacists and general physicians, that aims to facilitate stopping or lowering the prescription of medication for cardiovascular disease and/or diabetes in older patients. HYPOTHESIS: The researchers expect that the training program will lead to more proactive stopping or lowering the prescription of medication for cardiovascular disease and/or diabetes, and that patients will be more involved in the decision to stop or lower. STUDY DESIGN: The researchers will conduct a cluster-randomized trial in which 44 pharmacist-general practice teams in the Netherlands will be randomized to conducting medication reviews with 10 eligible patients as usual (control) or after receiving the deprescribing communication training program (intervention). STUDY POPULATION: People of 75 years and older using specific cardiometabolic medication and eligible for a medication review in The Netherlands will be included. INTERVENTION: The training program is based on previous work and applies models for patient-centered communication and shared decision making. The training consists of 5 modules with supportive tools. OUTCOME MEASURES: Primary outcome is the proportion of patients with deintensified cardiometabolic medication. Secondary outcomes include patient involvement in decision-making, healthcare professional communication skills assessed by the patient, medication-related outcomes, attitudes towards deprescribing, medication regimen complexity and health-related quality of life. Additional safety and cost parameters will be collected. SAMPLE SIZE/DATA-ANALYSIS: Based on a pilot study, the researchers have estimated that 167 patients are needed per study arm in the final intention-to-treat analysis using a mixed effects model. Taking loss to follow-up into account, 40 teams need to recruit 10 patients each. The researchers will conduct a baseline and a 6-months follow-up assessment, a process evaluation using the RE-AIM framework, and a cost effectiveness analysis.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 400
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 75 Years and older
Eligibility Inclusion criteria for the patients that receive a clinical medication review as part of the study: - 75 years or older - eligible for a clinical medication review according to the Dutch guidlines - using one or more of the following medications: a) sulfonylurea derivative; (b) insulin; (c) any 2 glucose-regulating medications; (d) any 2 blood pressure-lowering medications; (e) statin - managed and monitored by one of the participating HCP teams Exclusion criteria for the patients that receive a clinical medication review as part of the study: - diagnosed with type I diabetes - not understanding Dutch language - not giving or not able to give informed consent

Study Design


Intervention

Other:
communication training programme for healthcare providers
the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of patients in which one or more cardiometabolic medications is deprescribed proportion of patients per study arm in which one or more medications for diabetes or cardiovascular disease has been lowered or stopped collected retrospectively, 6 months after the start of the medication review
See also
  Status Clinical Trial Phase
Completed NCT03688542 - Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module N/A
Completed NCT02545257 - Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care N/A
Withdrawn NCT01932632 - Medication Minimization for Long-term Care Residents N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Active, not recruiting NCT04181879 - Appropriate Polypharmacy in Older People in Primary Care N/A
Not yet recruiting NCT03283735 - Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal N/A
Completed NCT02918058 - Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults N/A
Completed NCT03655405 - Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents N/A
Completed NCT04575155 - Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management N/A
Withdrawn NCT05816967 - Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients N/A
Completed NCT05616689 - Bundled Hyperpolypharmacy Deprescribing N/A
Terminated NCT04055896 - Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting N/A
Active, not recruiting NCT03052192 - Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
Completed NCT02866799 - Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy N/A
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Enrolling by invitation NCT05053815 - Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Active, not recruiting NCT04585191 - Reducing Treatment Risk in Older Adults With Diabetes N/A
Active, not recruiting NCT04120480 - Effectiveness of PGx Testing N/A
Recruiting NCT05609981 - Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems N/A
Recruiting NCT05501223 - Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic N/A